Search
The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online
The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online. HemaSphere is an open access journal, powered by the European Hematology Association and dedicated to support hematology patient care, research and education worldwide.
Read moreEHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy
The EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy brought together basic science, as well as translational and clinical research on November 23-25, 2017 in Amsterdam, The Netherlands.
Read moreEHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding
Meeting chairs, Carlo Balduini and Anna Falanga
The meeting was well attended by more than 100 participants coming from over 20 different countries
Delegate: Great meeting.
EHA-AHA hematology tutorial on Biology and Management of Myeloid Malignancies
In 2016, a new hematology center opened in Yerevan, which offers new services, enabling professionals working there to apply theoretical knowledge and advanced approaches in everyday practice.
Read moreEHA Mentorship Program eligibility
Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.
Read moreEHA-EBMT CAR T-cell Meeting
On this page, you can browse and/or download the 7th European CAR T-cell Meeting Sponsor Program. If the Sponsor Program does not display correctly, please click here or download the file.
Read moreCall for interest
As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.
Read moreAdding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- »